FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a universal integration vector SB7G_HIGH for cloning cDNA encoding variable domains of antibodies, comprising an expression cassette flanked by inverted repeats for integration with Sleeping beauty (SB) transposase in the eukaryotic cell genome, as well as to recombinant plasmid SB7G_HIGH_DEV_K57, obtained therefrom. Also disclosed is a recombinant monoclonal antibody DEV_K57, having virus-neutralizing activity on SARS-CoV-2 variants of Delta and Omicron.
EFFECT: invention is effective for producing genetic structures that provide more efficient synthesis and secretion of recombinant monoclonal antibodies in a eukaryotic producer cell line CHO-S, which is characterized by more effective post-translational modification and higher output of said recombinant antibodies having virus-neutralizing activity on SARS CoV 2 virus of Delta and Omicron variants.
3 cl, 13 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733832C1 |
| ARTIFICIAL ECTOS_SC2 GENE ENCODING AN ECTODOMAIN OF THE SARS-COV-2 CORONAVIRUS S GLYCOPROTEIN WITH A C-TERMINAL TRIMERIZATION DOMAIN, A RECOMBINANT PLASMID PSTEM-RVSV-ECTOS_SC2, WHICH PROVIDES EXPRESSION OF THE ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-ECTOS_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733834C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
